Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31242584 | 0.88 | PIM1 (0.36) | PIM1CHEK2MAP4K4HDAC6 | |
| SCHEMBL31242732 | 0.79 | PIM1 (0.36) | PIM1HRH4DYRK1AMAP4K4 | |
| SCHEMBL33526294 | 0.78 | — | — | |
| SCHEMBL31242781 | 0.78 | KRAS (0.33) | PIM1 | |
| SCHEMBL33525630 | 0.75 | PIM1 (0.30) | PIM1 | |
| SCHEMBL31085740 | 0.74 | MAP4K4 (0.47) | PIM1HRH4MAP4K4 | |
| SCHEMBL33525793 | 0.73 | — | — | |
| SCHEMBL31242393 | 0.70 | KRAS (0.35) | PIM1 | |
| SCHEMBL30587243 | 0.67 | — | — | |
| SCHEMBL26530411 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | PIM1 840/4885HRH4 400/4885DYRK1A 3089/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | PIM1 645/4885HRH4 451/4885DYRK1A 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.